Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged ...

Pfizer (NYSE:PFE) announced Friday that a late-stage clinical trial for inclacumab, its experimental therapy for the blood ...

For Q1 2018 (ended on March 31), Global Blood Therapeutics posted $41.6M ($0.87 per share) net losses compared to $23.3M ($0.60 per share) declines (for the same period a year prior).

A Comparison Of Global Blood Therapeutics' GBT440 And bluebird bio's LentiGlobin Apr. 07, 2017 4:14 PM ET Pfizer Inc. (PFE) Stock AES, BLUE, SCD PFE 11 Comments Emerging Equities 1.35K Follower s ...

* Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016 Source text for Eikon: Further ...

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 ...

* Global blood therapeutics reports recent business progress and provides second quarter 2016 financial results * Q2 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S Source text for Eikon ...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and ...